James Simsarian, MD
Neurology · Fairfax, VANPI 1235108986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,805 of the $173,013 with a category attached, or 64.0%. 30 manufacturers reported payments, led by Genentech USA, Inc. at 34.4% of the total. Reporting peaked in 2019 at $95,962 and has fallen 93.2% since, to $6,538 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $611.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$59K
- Biogen$51K
- Sanofi$24K
- Novartis$21K
- Bristol Myers Squibb$16K
- Teva Pharmaceuticals USA, Inc.$284
- plus $1K from 24 others
What the payments were for
- Consulting fees$47,46827%
- Speaking & faculty fees$110,80564%
- Grants$2,0001%
- Travel & lodging$6,4924%
- Food & beverage$5,8563%
- Education$3910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 60 | $59,440 |
| Biogen | 80 | $51,439 |
| Sanofi | 30 | $24,293 |
| Novartis | 46 | $20,572 |
| Bristol Myers Squibb | 22 | $15,868 |
| Teva Pharmaceuticals USA, Inc. | 4 | $284 |
| Lilly USA, LLC | 2 | $144 |
| EMD Serono, Inc. | 4 | $140 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Amgen(2 entities) | 3 | $82 |
| TG Therapeutics, Inc. | 3 | $71 |
| AstraZeneca | 3 | $69 |
| AbbVie | 3 | $63 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Banner Life Sciences, LLC | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| UCB, Inc. | 2 | $32 |
| Argenx US, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| GE HealthCare | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,013 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 46 | $665,298 |
| BetaseronInterferon Beta-1b | 28 | $346,318 |
| TecfideraDimethyl Fumarate | 23 | $213,748 |
| GilenyaFingolimod Hcl | 14 | $146,249 |
| AubagioTeriflunomide | 11 | $101,155 |
| CopaxoneGlatiramer Acetate | 11 | $62,680 |
| GlatopaGlatiramer Acetate | 18 | $51,226 |
| UbrelvyUbrogepant | 16 | $31,511 |
| Dalfampridine ErDalfampridine | 41 | $16,864 |
| Emgality PenGalcanezumab-Gnlm | 14 | $16,171 |
| Teriflunomide | 44 | $3,768 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $3,489 |
| Baclofen | 110 | $3,469 |
| Modafinil | 19 | $3,180 |
| Pregabalin | 60 | $2,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $51,439 | $213,74823 claims |
| NovartisGilenya | $20,572 | $146,24914 claims |
| SanofiAubagio | $24,293 | $101,15511 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $284 | $62,68011 claims |
| AbbVieUbrelvy | $63 | $31,51116 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $44823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Fairfax
- Rahul DaveFairfax$540K
- John RothrockFairfax$225K
- Laura CinskiFairfax$122K
- Abigail LawlerFairfax$107K
- Amy StoneFairfax$70K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.